Rankings
▼
Calendar
KLRS FY 2022 Earnings — Kalaris Therapeutics Inc Revenue & Financial Results | Market Cap Arena
KLRS
Kalaris Therapeutics Inc
$187M
FY 2022 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$0
Gross Profit
$0
Operating Income
-$14M
Net Income
-$15M
EPS (Diluted)
$-50.62
Cash Flow
Operating Cash Flow
-$10M
Free Cash Flow
-$10M
Stock-Based Comp.
$271,000
Balance Sheet
Total Assets
$4M
Total Liabilities
$34M
Stockholders' Equity
-$30M
Cash & Equivalents
$3M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$0
$0
—
Gross Profit
$0
-$1M
+100.0%
Operating Income
-$14M
-$170M
+91.8%
Net Income
-$15M
-$172M
+91.0%
← Q4 2021
All Quarters
Q1 2022 →